{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"7.336","value":"6.58"},{"groupId":"OG001","spread":"9.305","value":"10.64"}]}],"title":"Peginterferon alfa-2a dose reduction, n=171, 208"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"9.681","value":"12.43"},{"groupId":"OG001","spread":"8.984","value":"10.99"}]}],"title":"Ribavirin dose reduction, n=79, 189"}],"denoms":[{"counts":[{"groupId":"OG000","value":"171"},{"groupId":"OG001","value":"208"}],"units":"Participants"}],"description":"Time to first dose reduction was calculated as the time period from the first dose to the first dose reduction.","dispersionType":"Standard Deviation","groups":[{"description":"Participants completing the OL Phase were administered matching placebo tablets QD in combination with antiviral therapy (peginterferon alfa-2b and ribavirin) for a duration of either 24 or 48 weeks (for participants with Genotype 2/3) or 48 weeks (for participants with Non-Genotype 2/3).","id":"OG000","title":"Placebo+Antiviral Therapy: DB Phase"},{"description":"Participants completing the OL Phase continued on the same dose of eltrombopag received in the OL Phase (dose that effectively raised platelets to \\>=100 Gi/L) in combination with antiviral therapy (peginterferon alfa-2b and ribavirin) for a duration of either 24 or 48 weeks (for participants with Genotype 2/3) or 48 weeks (for participants with Non-Genotype 2/3).","id":"OG001","title":"Eltrombopag+Antiviral Therapy: DB Phase"}],"paramType":"MEAN","populationDescription":"ITT Population. Only those participants with dose reductions were analyzed.","reportingStatus":"POSTED","timeFrame":"From Baseline up to Week 48 or Week 72 (for participants with Genotype 2/3) or up to Week 72 (for participants with Non-Genotype 2/3)","title":"Time to First Dose Reduction of Peginterferon Alfa-2a and Ribavirin Therapy in the DB Phase","type":"SECONDARY","unitOfMeasure":"weeks"}